Oncotelic Therapeutics, Inc. (OTLC) Return on equity 2021–2024
Oncotelic Therapeutics, Inc. (OTLC) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-65.2%FY2024 · since FY2021: -80.7% → -65.2%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2024 | -65.2% | — |
| FY2021 | -80.7% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More OTLC financial trends
OTLC RevenueOTLC Net incomeOTLC Net marginOTLC Gross profitOTLC Gross marginOTLC Operating incomeOTLC Operating marginOTLC Operating cash flowOTLC Free cash flowOTLC Capital expendituresOTLC Stock buybacksOTLC Dividends paidOTLC Total assetsOTLC Total liabilitiesOTLC Shareholders’ equityOTLC overview →